Five-year follow-up data from the pivotal Vyxeos liposomal study1/4 Next Chapter
Real-world benefits of Vyxeos liposomal in high-risk* AML: Part 1, Italy2/4 Next Chapter
Real-world benefits of Vyxeos liposomal in high-risk* AML: Part 2, France3/4 Next Chapter
Real-world benefits of Vyxeos liposomal in high-risk* AML: Part 3, Germany4/4 Leave Feedback
Learning Objectives & Overview
The pivotal trial of Vyxeos liposomal (daunorubicin 44 mg / cytarabine 100 mg powder for concentrate for solution for infusion) demonstrated the significant survival and remission benefits it provides over conventional chemotherapy in high-risk* AML.1
In this touchFEATURE activity, four educational videos highlight the long-term efficacy and real-world effectiveness of Vyxeos liposomal, supporting the pivotal clinical trial results.2–4
*High-risk AML is defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
After watching this activity, participants should be better able to:
- Describe the key findings from the 5-year follow-up of the pivotal, phase 3 trial of Vyxeos liposomal for the treatment of high-risk* AML.
- Describe the key findings from three real-world studies of Vyxeos liposomal for the treatment of high-risk* AML in Italy, Germany and France.
- Discuss how the clinical trial benefits of Vyxeos liposomal in high-risk* AML translate into real-world practice.
*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email to firstname.lastname@example.org
- Lancet JE, et al. Vyxeos liposomal (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692.
- Lancet JE, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491.
- Chiche E, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5:176–184.
- Guolo F, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10:96.